ES2516665T3 - Sistema de administración basado en glutatión - Google Patents

Sistema de administración basado en glutatión Download PDF

Info

Publication number
ES2516665T3
ES2516665T3 ES05292820.7T ES05292820T ES2516665T3 ES 2516665 T3 ES2516665 T3 ES 2516665T3 ES 05292820 T ES05292820 T ES 05292820T ES 2516665 T3 ES2516665 T3 ES 2516665T3
Authority
ES
Spain
Prior art keywords
tocopherol
tocotrienol
polyethylene glycol
succinate
acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES05292820.7T
Other languages
English (en)
Inventor
Ae-June Wang
Chi-Heng Jian
Shyh-Dar Li
Yi-Fong Lin
Shih-Jr Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industrial Technology Research Institute ITRI
Original Assignee
Industrial Technology Research Institute ITRI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industrial Technology Research Institute ITRI filed Critical Industrial Technology Research Institute ITRI
Application granted granted Critical
Publication of ES2516665T3 publication Critical patent/ES2516665T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less

Abstract

Sistema de administración, comprendiendo: Un portador; y, ligando injertado sobre el mismo, donde el ligando comprende una fracción que comprende un derivado de vitamina E o un derivado de fosfolípido, un derivado de polietilenglicol conectado a este, y glutatión conectado al derivado de polietilenglicol, donde el derivado de vitamina E es seleccionado del grupo consistente en α-tocoferol, β-tocoferol, γ-tocoferol, δ-tocoferol, α-tocotrienol, β-tocotrienol, γ-tocotrienol, δ-tocotrienol, succinato de α-tocoferol, succinato de β-tocoferol, succinato de γ- tocoferol, succinato de δ-tocoferol, succinato de α-tocotrienol, succinato de β-tocotrienol, succinato de γ-tocotrienol, succinato de δ-tocotrienol, acetato de δ-tocoferol, acetato de β-tocoferol, acetato de γ-tocoferol, acetato de δ-tocoferol, acetato de α-tocotrienol, acetato de β-tocotrienol, acetato de γ-tocotrienol, acetato de δ-tocotrienol, nicotinato de α- tocoferol, nicotinato de β-tocoferol, nicotinato de γ-tocoferol, nicotinato de δ-tocoferol, nicotinato de α-tocotrienol, nicotinato de β-tocotrienol, nicotinato de γ-tocotrienol, nicotinato de δ-tocotrienol, fosfato de α-tocoferol, fosfato de β- tocoferol, fosfato de γ-tocoferol, fosfato de δ-tocoferol, fosfato de δ-tocotrienol, fosfato de β-tocotrienol, fosfato de γ- tocotrienol, o fosfato de δ-tocotrienol, donde el derivado de fosfolípido es seleccionado del grupo consistente en un derivado de fosfolípido con fórmula (I): donde A1 es esfingosina y R1 es octanoil o palmitoilo, y un derivado de fosfolípido con fórmula (II):**Fórmula** donde A2 es fosfoetanoamina y R2 es miristoilo, palmitoilo, estearoil, u oleoil, y donde el derivado de polietilenglicol es seleccionado del grupo consistente en el polietilenglicol, polietilenglicol que comprende ácido carboxílico, polietilenglicol que comprende maleimida, polietilenglicol que comprende PDP, polietilenglicol que comprende amida, y polietilenglicol que comprende biotina.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7

Claims (1)

  1. imagen1
    imagen2
    imagen3
    imagen4
    imagen5
ES05292820.7T 2005-12-19 2005-12-29 Sistema de administración basado en glutatión Active ES2516665T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US303934 2005-12-19
US11/303,934 US7446096B2 (en) 2005-12-19 2005-12-19 Glutathione based delivery system

Publications (1)

Publication Number Publication Date
ES2516665T3 true ES2516665T3 (es) 2014-10-31

Family

ID=36217526

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05292820.7T Active ES2516665T3 (es) 2005-12-19 2005-12-29 Sistema de administración basado en glutatión

Country Status (11)

Country Link
US (4) US7446096B2 (es)
EP (2) EP2837384A1 (es)
JP (2) JP4773200B2 (es)
CN (2) CN101385859B (es)
CY (1) CY1115542T1 (es)
DK (1) DK1891962T3 (es)
ES (1) ES2516665T3 (es)
PL (1) PL1891962T3 (es)
PT (1) PT1891962E (es)
SI (1) SI1891962T1 (es)
TW (1) TWI365754B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR549901A0 (en) * 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
US20040057983A1 (en) 2002-09-25 2004-03-25 David Schmidt Biomolecular wearable apparatus
WO2005084678A1 (en) * 2004-03-03 2005-09-15 Vital Health Sciences Pty Ltd Alkaloid formulations
KR101238703B1 (ko) * 2004-08-03 2013-03-04 바이탈 헬스 사이언시즈 피티와이 리미티드 경구 투여용 담체
US20090239827A1 (en) * 2005-03-03 2009-09-24 Esra Ogru Compounds having lipid lowering properties
KR20080019228A (ko) 2005-06-17 2008-03-03 바이탈 헬스 사이언시즈 피티와이 리미티드 하나 이상의 디 및/또는 모노-(전자전달제) 인산염 유도체또는 그의 착염을 함유하는 담체
US8067380B2 (en) * 2005-12-19 2011-11-29 Industrial Technology Research Institute Glutathione-based delivery system
US7446096B2 (en) * 2005-12-19 2008-11-04 Industrial Technology Research Institute Glutathione based delivery system
DK2308514T3 (da) * 2007-03-23 2013-09-02 To Bbb Holding B V Konjugater til målrettet lægemiddeltransport gennem blod-hjerne barrieren
FR2926725B1 (fr) * 2008-01-25 2010-09-03 Biochimie Appliquee Soc Compositions cosmetiques et/ou dermatologiques cicatrisantes
US8602961B2 (en) * 2008-05-15 2013-12-10 Lifewave Products Llc Apparatus and method of stimulating elevation of glutathione levels in a subject
KR101727333B1 (ko) * 2008-11-26 2017-04-14 추가이 세이야쿠 가부시키가이샤 베시클 제제
EP2368989A4 (en) 2008-11-26 2012-09-26 Chugai Pharmaceutical Co Ltd OLOGORIBONUCLEOTIDE OR PEPTIDE NUCLEIC ACID CAPABLE OF INHIBITING HEPATITIS C VIRUS ACTIVITY
WO2010095940A2 (en) * 2009-02-20 2010-08-26 To-Bbb Holding B.V. Glutathione-based drug delivery system
AU2011213557B2 (en) 2010-02-05 2015-05-07 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
CN102821791B (zh) * 2010-03-30 2015-06-17 磷肌酸有限公司 透皮递送贴剂
EP2685992A4 (en) 2011-03-15 2014-09-10 Phosphagenics Ltd AMINO-QUINOLINES AS KINASE INHIBITORS
GB201302427D0 (en) * 2013-02-12 2013-03-27 Midatech Ltd Nanoparticle delivery compositions
EP3038657A2 (en) 2013-08-28 2016-07-06 Bioasis Technologies Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
WO2015054280A1 (en) 2013-10-08 2015-04-16 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US10765755B1 (en) * 2013-11-20 2020-09-08 University Of South Florida Preparation and characterization of methylene blue nanoparticles for Alzheimer's disease and other tauopathies
EP4218742A1 (en) 2014-04-04 2023-08-02 AI Therapeutics, Inc. An inhalable rapamycin formulation for treating age-related conditions
WO2015154897A1 (en) * 2014-04-08 2015-10-15 Wolfgang Stremmel Means and methods for treating disorders of copper metabolism
EP3131944B1 (en) * 2014-04-17 2018-12-05 The Corporation OF Mercer University Vitamin e-based nanocarriers for drug delivery and methods of making and using the same
KR20170095807A (ko) 2014-10-07 2017-08-23 램 테라퓨틱스, 인코포레이티드 폐 고혈압의 치료를 위한 흡입가능 라파마이신 제제
US10758520B1 (en) 2015-05-20 2020-09-01 University Of South Florida Glutathione-coated nanoparticles for delivery of MKT-077 across the blood-brain barrier
CA3007587C (en) 2015-12-09 2023-12-05 Phosphagenics Limited Pharmaceutical formulation
BR112019012946A2 (pt) 2016-12-21 2019-11-26 Avecho Biotechnology Ltd processo
US10226442B2 (en) 2017-07-10 2019-03-12 Syneurx International (Taiwan) Corp. Lithium salts of N-substituted glycine compounds and uses thereof
US10842755B2 (en) 2018-03-23 2020-11-24 University Of South Carolina Nanoparticles for brain targeted drug delivery
WO2021054927A2 (en) * 2018-08-10 2021-03-25 South Dakota Board Of Regents Glutathione-cholesterol derivatives as brain targeting agents
WO2020242217A1 (ko) * 2019-05-28 2020-12-03 울산과학기술원 글루타치온-ｓ-전이효소 및 표적 세포 또는 표적 단백질 결합능을 갖는 단백질을 포함하는 리포좀 및 이의 용도
EP3954393A1 (en) 2020-08-13 2022-02-16 Bioasis Technologies Inc. Combination therapies for delivery across the blood brain barrier
TW202228792A (zh) 2020-10-09 2022-08-01 殷漢生技股份有限公司 吸入用奈米載體製劑

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60142915A (ja) 1983-12-28 1985-07-29 Lion Corp 口腔用組成物
JPS632922A (ja) 1986-06-20 1988-01-07 Yamanouchi Pharmaceut Co Ltd ドラツグキヤリア
JPH0714865B2 (ja) * 1986-10-28 1995-02-22 武田薬品工業株式会社 リポソ−ム製剤およびその製造法
FR2627385B3 (fr) 1988-02-23 1991-08-23 Serobiologiques Lab Sa Composition notamment utile comme matiere de base pour la preparation de compositions pharmaceutiques, notamment dermatologiques et/ou cosmetiques
US5695751A (en) 1993-04-08 1997-12-09 Cornell Research Foundation, Inc. Enhancing delivery of large neutral amino acid drugs
JPH0834779A (ja) * 1994-05-20 1996-02-06 Senju Pharmaceut Co Ltd トコフェロール誘導体
US6653331B2 (en) 1996-07-03 2003-11-25 Pharmacia & Upjohn Company Targeted drug delivery using sulfonamide derivatives
AU730216B2 (en) * 1996-09-01 2001-03-01 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
EP0932390A1 (en) * 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
US6228347B1 (en) 1997-12-01 2001-05-08 Thione International, Inc. Antioxidant gel for gingival conditions
EP1072608B1 (en) 1998-04-16 2005-06-15 Teijin Limited Glutathione derivatives and dosage forms thereof
JP2004323486A (ja) * 2003-04-30 2004-11-18 National Institute Of Advanced Industrial & Technology 網膜及び／又はブドウ膜疾患の予防乃至治療用点眼薬
CN100515390C (zh) * 2005-04-14 2009-07-22 蔡海德 垂体前叶肾上腺皮质提取物纳米脂质体组合药物及其制备方法和用途
US7446096B2 (en) * 2005-12-19 2008-11-04 Industrial Technology Research Institute Glutathione based delivery system
US8067380B2 (en) * 2005-12-19 2011-11-29 Industrial Technology Research Institute Glutathione-based delivery system

Also Published As

Publication number Publication date
US7700564B2 (en) 2010-04-20
EP2837384A1 (en) 2015-02-18
US20080095836A1 (en) 2008-04-24
US20090060991A1 (en) 2009-03-05
JP5394944B2 (ja) 2014-01-22
US20100166849A1 (en) 2010-07-01
TWI365754B (en) 2012-06-11
US20070141133A1 (en) 2007-06-21
PT1891962E (pt) 2014-11-11
SI1891962T1 (sl) 2014-12-31
CN1985804B (zh) 2014-05-14
JP2007169252A (ja) 2007-07-05
CN101385859A (zh) 2009-03-18
CY1115542T1 (el) 2017-01-04
JP4773200B2 (ja) 2011-09-14
US8569239B2 (en) 2013-10-29
PL1891962T3 (pl) 2015-01-30
CN101385859B (zh) 2011-12-07
US7446096B2 (en) 2008-11-04
JP2010150264A (ja) 2010-07-08
CN1985804A (zh) 2007-06-27
EP1891962A1 (en) 2008-02-27
US7704956B2 (en) 2010-04-27
EP1891962B1 (en) 2014-08-13
DK1891962T3 (da) 2014-10-13

Similar Documents

Publication Publication Date Title
ES2516665T3 (es) Sistema de administración basado en glutatión
Dorta et al. The interaction of flavonoids with mitochondria: effects on energetic processes
ES2193730T3 (es) Ligandos de receptores de la hormona tiroidea y de glucocortioides para el tratamiento de desordenes metabolicos.
BR0014225A (pt) Derivados de pirazol
ES2668826T3 (es) Lípidos, complejos lipídicos y uso de los mismos
RS50484B (sr) Nova spiro jedinjenja
BRPI0509258A8 (pt) composto de 8-oxoadenina 9-substituída
BRPI0418330A (pt) composições sólidas de drogas de solubilidade baixa e poloxámeros
CY1110751T1 (el) Φαρμακευτικο σκευασμα που περιλαμβανει μικροκαψουλες απο στατινες εναιωρημενες σε αλκυλεστερες πολυακορεστων λιπαρων οξεων (pufa)
RS65604A (en) Novel fluorene carboxylic acid esters, methods for the production thereof, and use of the same as pharmaceuticals
TW200505890A (en) Breast cancer-resistant protein inhibitor
DE60111964D1 (de) Nahrungsergänzungsmittel auf Basis von schwarzem Johannisbeeröl
BRPI0620229A8 (pt) formulação
DE60219524D1 (de) Kosmetische zusammensetzungen enthaltend ein cyclodipeptid
BRPI0418474A (pt) solução aquosa parenteral estável
CO5570675A2 (es) Compuestos sustituidos de benzimidazolo y su uso para el tratamiento del cancer
GT200500120A (es) Prodrogas de estriol y estetrol
DK0577305T3 (da) Antioxidantsammensætninger
BR0210686A (pt) Sistemas df alvejamento por perácido com estabilidade avançada para aplicações têxteis
AR106545A2 (es) Composición farmacéutica que comprende derivados de metastina
BR0312585A (pt) Processo de preparação de alquil alquenoato éster
EA200501232A1 (ru) Новые трициклические соединения азепина, способ их получения и содержащие их фармацевтические композиции
ATE385316T1 (de) Stabilisierung von biologischen flüssigkeiten durch zusatz von sterinestern
CA2700867A1 (en) Use of vitamin b3 and vitamin c to stabilize quercetin in an aqueous solution
BRPI0510636A (pt) doadores de ácido para tingimento de poliamida